[{"address1": "1 Commonwealth Lane, No. 08-22", "city": "Singapore", "zip": "149544", "country": "Singapore", "phone": "65 6250 7738", "website": "https://w2.cytomed.sg", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.", "maxAge": 86400, "priceHint": 4, "previousClose": 1.92, "open": 1.97, "dayLow": 1.97, "dayHigh": 1.98, "regularMarketPreviousClose": 1.92, "regularMarketOpen": 1.97, "regularMarketDayLow": 1.97, "regularMarketDayHigh": 1.98, "forwardPE": -11.6470585, "volume": 2706, "regularMarketVolume": 2706, "averageVolume": 4622, "averageVolume10days": 4500, "averageDailyVolume10Day": 4500, "marketCap": 22849200, "fiftyTwoWeekLow": 1.89, "fiftyTwoWeekHigh": 9.25, "priceToSalesTrailing12Months": 45.00213, "fiftyDayAverage": 2.07988, "twoHundredDayAverage": 3.004305, "currency": "USD", "enterpriseValue": 14301199, "floatShares": 3546127, "sharesOutstanding": 11540000, "sharesShort": 38468, "sharesShortPriorMonth": 39352, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0033000002, "heldPercentInsiders": 0.69271004, "heldPercentInstitutions": 0.00042, "shortRatio": 5.68, "shortPercentOfFloat": 0.0226, "impliedSharesOutstanding": 11600100, "bookValue": 0.975, "priceToBook": 2.030769, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -4132896, "trailingEps": -0.29, "forwardEps": -0.17, "enterpriseToRevenue": 28.167, "enterpriseToEbitda": -4.129, "52WeekChange": -0.31010455, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GDTC", "underlyingSymbol": "GDTC", "shortName": "CytoMed Therapeutics Limited", "longName": "CytoMed Therapeutics Limited", "firstTradeDateEpochUtc": 1681479000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "5fbb5a07-c64c-3457-b39c-0446de45b69d", "messageBoardId": "finmb_647650276", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.98, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 8995067, "totalCashPerShare": 0.779, "ebitda": -3463885, "totalDebt": 448022, "quickRatio": 12.832, "currentRatio": 14.083, "totalRevenue": 507736, "debtToEquity": 3.984, "revenuePerShare": 0.048, "returnOnAssets": -0.27299, "returnOnEquity": -0.69873, "freeCashflow": -2043202, "operatingCashflow": -3432830, "revenueGrowth": -0.228, "grossMargins": 0.99266, "operatingMargins": -8.11267, "financialCurrency": "SGD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]